Shanghai Cancer Hospital, China — CureCurrent

How to interpret these research links

Connected source records

The exact organization name Shanghai Cancer Hospital, China appears in 10 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials10

Recruiting shown2

Roles2

SourceClinicalTrials.gov

Clinical trials

10 shown

A Study of the Safety and Efficacy of Pemetrexed Combined with Nivolumab Via Intraventricular Injection for the Treatment of Refractory Non-squamous Non-small Cell Lung Cancer with Leptomeningeal MetastasesNCT06901817 · lead sponsor · 2025-03-01

Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung CancerNCT05800223 · lead sponsor · 2023-01-01

Efficacy of SRT as Salvage Therapy in Patients With Brain Oligo-progression of EGFR-mutant Non-small Cell Lung Cancer After Failure of the Third-generation EGFR-TKIsNCT04519983 · lead sponsor · 2022-01-01

Efficacy and Safety of Platinum-based Chemotherapy + Bevacizumab + Durvalumab, and Salvage SBRT for IV Non-Small Cell Lung Cancer Patients With EGFR Mutations After Failure of First Line Osimertinib: A Multicenter, Prospective, Phase II Clinical StudyNCT04517526 · lead sponsor · 2020-11-01

Efficacy and Safety of Sintilimab With or Without Radiotherapy in Patients With Recurrent or IV NSCLC (EGFR -, ALK -) After Failure of Platinum-based Chemotherapy: A Randomized,Open Labled, Phase II Clinical StudyNCT04513301 · lead sponsor · 2020-01-01

Neoadjuvant Study of Nab-paclitaxel Plus Carboplatin in Breast CancerNCT01625429 · lead sponsor · 2012-06-01

Prospective Study on Factors Predicting Chemo-Radiotherapy Induced Pulmonary and Esophageal InjuryNCT00631839 · lead sponsor · 2002-01-01

Evaluating the Efficacy of Structured Exercise Interventions in Alleviating Aromatase Inhibitor-Induced Arthralgia in Breast Cancer Survivors: a Pilot Study ProtocolNCT06754293 · collaborator · 2024-12-01

ACTIVE_NOT_RECRUITING

Efficacy Study of Comprehensive Rehabilitation Program Plus Chemotherapy in Postoperative NSCLC PatientsNCT03372694 · collaborator · 2016-10-01

Efficacy Study of Comprehensive Rehabilitation Program in Postoperative NSCLC PatientsNCT03244605 · collaborator · 2016-10-01

Drugs studied in this sponsor's trials

2 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Shanghai Cancer Hospital, China as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.

placebo2

paclitaxel protein-bound1

placebo RxCUI 8375 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 2 trials paclitaxel protein-bound RxCUI 486610 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

lead sponsor7

collaborator3

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.